Neuravi has announced that Robert A Stern has joined the company’s board of directors.
Stern has more than 25 years of experience as a senior executive for medtech and biotech health care companies, including deep neurovascular experience. He is currently chief executive officer and president of Vascular Dynamics, a venture-backed company developing a novel implantable technology designed to manage resistant hypertension. Prior to Vascular Dynamics he held several senior executive roles in publicly traded companies, including president and chief operating officer at Micrus Endovascular, a manufacturer of medical devices to treat cerebrovascular disease, which was acquired by Johnson & Johnson in 2010. He has also served as a director on the boards of Reverse Medical and Flexible Stenting Solutions.
“We are thrilled that Robert has joined the Neuravi board at this important time in the company’s growth. His track record of value creation and direct neurovascular experience are key as we embark upon European commercialisation of the EmboTrap revascularisation device and the initiation of ARISE II, our international clinical trial,” said Eamon Brady, chief executive officer.
Stern’s organisational experience includes spearheading global licensing and distribution agreements, forging corporate alliances, improving profitability, and developing corporate infrastructure for companies in a variety of industries. In addition, he has played an instrumental role in initial public offerings and acquisitions.
“I am very pleased to be working with a company that will truly make a difference in improving the lives of patients suffering from acute ischaemic stroke,” said Stern. “With recent clinical data reinforcing the value of device intervention for stroke patients, this is an exciting time for companies developing thrombectomy solutions, and Neuravi’s talented team has made significant progress with its innovative stent-retriever. I look forward to helping navigate this rapidly growing field.”
